Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Ovidiu C. Andronesi"'
Autor:
Christian Richter, Ovidiu C. Andronesi, Ronald J.H. Borra, Felix Voigt, Steffen Löck, Dan G. Duda, Alexander R. Guimaraes, Theodore S. Hong, Thomas R. Bortfeld, Joao Seco
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 18, Iss , Pp 113-119 (2019)
Background and purpose: Previous MRI studies have shown a substantial decrease in normal-tissue uptake of a hepatobiliary-directed contrast agent 6–9 weeks after liver irradiation. In this prospective clinical study, we investigated whether this ef
Externí odkaz:
https://doaj.org/article/82c22c5cea82474bb9a351c3cc70481f
Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients
Autor:
Ovidiu C. Andronesi, Katharine Nicholson, Kourosh Jafari-Khouzani, Wolfgang Bogner, Jing Wang, James Chan, Eric A. Macklin, Mark Levine-Weinberg, Christopher Breen, Michael A. Schwarzschild, Merit Cudkowicz, Bruce R. Rosen, Sabrina Paganoni, Eva-Maria Ratai
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Background: Oxidative stress and protein aggregation are key mechanisms in amyotrophic lateral sclerosis (ALS) disease. Reduced glutathione (GSH) is the most important intracellular antioxidant that protects neurons from reactive oxygen species. We h
Externí odkaz:
https://doaj.org/article/95731cf9e77c4393b38ac41422e028cd
Autor:
Ovidiu C. Andronesi, Isabel C. Arrillaga-Romany, K. Ina Ly, Wolfgang Bogner, Eva M. Ratai, Kara Reitz, A. John Iafrate, Jorg Dietrich, Elizabeth R. Gerstner, Andrew S. Chi, Bruce R. Rosen, Patrick Y. Wen, Daniel P. Cahill, Tracy T. Batchelor
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-9 (2018)
Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1) entered recently clinical trials for treatment of gliomas. Here, the authors apply a MRS imaging method for 2HG detection and assessement of the pharmacodynamic effects of the mutant IDH1 inhibit
Externí odkaz:
https://doaj.org/article/b6420b3093174f1f828f783b189caae2
Autor:
Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor
Publikováno v:
npj Precision Oncology, Vol 1, Iss 1, Pp 1-9 (2017)
Metabolic imaging reveals anti-angiogenic (AA) therapy mechanisms in glioblastoma (GBM) GBM is the most common and aggressive type of malignant primary brain tumors (glioma). Patients with GBM have less than 5% survival at 5 years with the best exist
Externí odkaz:
https://doaj.org/article/cff8891abc634b19b196fe665c1e1ac0
Autor:
Daniel P. Cahill, Bruce R. Rosen, Andrew S. Chi, William G. Kaelin, Elizabeth R. Gerstner, Tracy T. Batchelor, Jorg Dietrich, A. John Iafrate, Matthew G. Vander Heiden, Małgorzata Marjańska, Wolfgang Bogner, Franziska Loebel, Ovidiu C. Andronesi
Purpose: Measurements of objective response rates are critical to evaluate new glioma therapies. The hallmark metabolic alteration in gliomas with mutant isocitrate dehydrogenase (IDH) is the overproduction of oncometabolite 2-hydroxyglutarate (2HG),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b083557709dafe28ff9b79613bdaddb
https://doi.org/10.1158/1078-0432.c.6524276.v1
https://doi.org/10.1158/1078-0432.c.6524276.v1
Autor:
Daniel P. Cahill, Bruce R. Rosen, Andrew S. Chi, William G. Kaelin, Elizabeth R. Gerstner, Tracy T. Batchelor, Jorg Dietrich, A. John Iafrate, Matthew G. Vander Heiden, Małgorzata Marjańska, Wolfgang Bogner, Franziska Loebel, Ovidiu C. Andronesi
This file contains 3 Tables and 9 Figures with additional results and details of analysis related to the main results presented in the manuscript. The complete list of figures and tables is provided below. Table 1S. Baseline metabolite levels relativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a887dcf8c4342131e422d89f49095d
https://doi.org/10.1158/1078-0432.22459658.v1
https://doi.org/10.1158/1078-0432.22459658.v1
Autor:
A. Gregory Sorensen, Rakesh K. Jain, Tracy T. Batchelor, Dominique L. Jennings, Ovidiu C. Andronesi, Eva-Maria Ratai, Ciprian Catana, Heisoog Kim
Supplementary Appendix, Table 1, Figure Legends 1-4 from Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6fcaebde5a7e5c79cb777d4644edc2
https://doi.org/10.1158/0008-5472.22394015.v1
https://doi.org/10.1158/0008-5472.22394015.v1
Autor:
Rakesh K. Jain, Tracy T. Batchelor, A. Gregory Sorensen, E. Tessa Hedley-Whyte, Scott R. Plotkin, Patrick Y. Wen, Matthew P. Frosch, Ovidiu C. Andronesi, Ladan Fazlollahi, Pavan K. Auluck, Dan G. Duda, Walid S. Kamoun, Matija Snuderl, Emmanuelle di Tomaso
Supplementary Figure 1 from Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59721690b47705f9aa52e7abf374775e
https://doi.org/10.1158/0008-5472.22389077.v1
https://doi.org/10.1158/0008-5472.22389077.v1
Autor:
A. Gregory Sorensen, Rakesh K. Jain, Tracy T. Batchelor, Dominique L. Jennings, Ovidiu C. Andronesi, Eva-Maria Ratai, Ciprian Catana, Heisoog Kim
Supplementary Methods, Figures 1-4 from Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dfc9016c3bb1b951cd14d991665c100
https://doi.org/10.1158/0008-5472.22394012.v1
https://doi.org/10.1158/0008-5472.22394012.v1
Autor:
Rakesh K. Jain, Tracy T. Batchelor, A. Gregory Sorensen, E. Tessa Hedley-Whyte, Scott R. Plotkin, Patrick Y. Wen, Matthew P. Frosch, Ovidiu C. Andronesi, Ladan Fazlollahi, Pavan K. Auluck, Dan G. Duda, Walid S. Kamoun, Matija Snuderl, Emmanuelle di Tomaso
Supplementary Figure 2 from Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344db8793643458f1ba1ea95461ad1b6
https://doi.org/10.1158/0008-5472.22389074.v1
https://doi.org/10.1158/0008-5472.22389074.v1